Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 5, 2025, after the close
10-Q filed Aug 5, 2025, 36 days after period end · 0001558370-25-010281
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $101.69M | $36.84M | $26.89M | $29.82M |
| Net Income | $59.61M | -$1.03M | -$6.60M | -$13.49M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| $3.28 |
| -$0.06 |
| -$0.38 |
| -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
